Piper Sandler analyst Biren Amin assumed coverage of Regeneron (REGN) with an Overweight rating and $875 price target Piper views Regeneron as a “top-tier large-cap biotech with one of the most durable growth engines in the sector.” The firm expects “continued dominance” of Dupixent and highlights the transition of Eylea franchise to Eylea HD. Regeneron has several “high-potential pipeline assets that are currently undervalued by consensus,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan
- Get Ready for a $5.7 Trillion ‘Triple-Witching’ Event on Friday
- Regeneron price target raised to $825 from $800 at Wells Fargo
- Vertex Pharmaceuticals price target raised to $550 from $515 at Wells Fargo
- Amgen price target raised to $390 from $375 at Wells Fargo